In the latest newsletter from the International Law Office, Lindahl’s Jonas Löfgren, Annie Kabala and Natalie Tell provides an update on recent developments in Sweden which further increases pricing uncertainty for orphan drugs.
These cookies are necessary for the functionality of the site and cannot be disabled.
We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.